Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.67 |
| ▸ | MELK | Q14680 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | IDE | P14735 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13648862 | 0.81 | HRH3 (1.00) | HRH3 | |
| Hydrochloric Acid SCHEMBL3967429 | 0.80 | HRH3 (0.97) | HRH3 | |
| SCHEMBL13648925 | 0.74 | HRH3 (1.00) | HRH3 | |
| SCHEMBL13648846 | 0.74 | HRH3 (1.00) | HRH3 | |
| Hydrochloric Acid SCHEMBL3973108 | 0.74 | HRH3 (0.98) | HRH3 | |
| Hydrochloric Acid SCHEMBL3971412 | 0.73 | HRH3 (0.97) | HRH3 | |
| SCHEMBL13648774 | 0.71 | HRH3 (1.00) | HRH3 | |
| SCHEMBL27892911 | 0.70 | HRH3 (0.71) | HRH3 | |
| Hydrochloric Acid SCHEMBL3971036 | 0.70 | HRH3 (0.97) | HRH3 | |
| SCHEMBL13648926 | 0.68 | HRH3 (0.67) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370202-B1 | XENON GAS FOR USE IN THE TREATMENT OF GLIOMAS | UNIV HEIDELBERG (DE) | 2026-03-18 | — | — | EP | claimed |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | ALTO NEUROSCIENCE INC (US) | 2026-03-05 | — | — | US | claimed |
| US-20250000896-A1 | Xenon Gas for Use in the Treatment of Gliomas | Universität Heidelberg (DE) | 2025-01-02 | — | — | US | claimed |
| EP-4370202-A1 | XENON GAS FOR USE IN THE TREATMENT OF GLIOMAS | Universität Heidelberg (DE) | 2024-05-22 | — | — | EP | claimed |
| WO-2023285170-A1 | XENON GAS FOR USE IN THE TREATMENT OF GLIOMAS | Universität Heidelberg (DE) | 2023-01-19 | — | — | WO | claimed |
| EP-4119191-A1 | XENON GAS FOR USE IN THE TREATMENT OF GLIOMAS | Universität Heidelberg (DE) | 2023-01-18 | — | — | EP | claimed |
| CN-121902886-B | Digital impulse neuron, impulse neural network and realization method thereof | 中国科学技术大学 | 2026-05-22 | — | — | CN | disclosed |
| CN-122036563-A | Synthesis method of aryl F-18 marked sulfonyl chloride and application of aryl F-18 marked sulfonyl chloride in amine compound marking | 四川大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4370202-B1 | XENON GAS FOR USE IN THE TREATMENT OF GLIOMAS | UNIV HEIDELBERG (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | ALTO NEUROSCIENCE INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250295699-A1 | METHODS AND COMPOSITIONS FOR TREATING CORTICAL HYPEREXCITABILITY AND REVERSING STROKE-INDUCED CHANGES IN GENE EXPRESSION AND PROTEIN EXPRESSION | SANBIO, INC. (US) | 2025-09-25 | — | — | US | disclosed |
| CN-118615253-B | Pirennet microsphere based on multiple emulsion process and preparation method and application thereof | 四川大学华西医院 | 2025-06-03 | — | — | CN | disclosed |
| CN-119881321-A | Application of AMPAR protein group in response to terahertz waves | 中国人民解放军军事科学院军事医学研究院 | 2025-04-25 | — | — | CN | disclosed |
| US-6015835-A | ADMINISTERING TAURINE, HOMOTAURINE, AND/OR METHIONINE | MEDDISS, INCORPORATED (JP) | 2000-01-18 | — | — | US | disclosed |
| EP-0797992-A2 | Use of taurine, homotaurine and/or methionine for inducing analgesia or anesthesia and treating or preventing ischaemic injury | Meddiss, Inc. (JP) | 1997-10-01 | — | — | EP | disclosed |
| US-5364876-A | Tranquilizers, analgesics, learning enhancement | GUILFORD PHARMACEUTICALS INC. (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0587789-A4 | METHODS OF TREATING INJURY TO THE CENTRAL NERVOUS SYSTEM | GENSIA INC (US) | 1994-09-07 | — | — | EP | disclosed |
| EP-0587789-A1 | METHODS OF TREATING INJURY TO THE CENTRAL NERVOUS SYSTEM | GENSIA, INC. (US) | 1994-03-23 | — | — | EP | disclosed |
| US-5236908-A | Using adenosine antagonist | GENSIA PHARMACEUTICALS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| WO-1992021337-A1 | METHODS OF TREATING INJURY TO THE CENTRAL NERVOUS SYSTEM | GENSIA, INC. (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | NTRK2, BDNF, GRIN2A | HRH3 597/4885MELK 1407/4885ALDH1A1 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.